Krista Davis Sells 1,622 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $82.40, for a total transaction of $133,652.80. Following the completion of the transaction, the senior vice president owned 58,564 shares in the company, valued at approximately $4,825,673.60. This trade represents a 2.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

ANI Pharmaceuticals Stock Up 0.0%

Shares of ANI Pharmaceuticals stock opened at $82.85 on Friday. ANI Pharmaceuticals, Inc. has a 12-month low of $52.74 and a 12-month high of $99.50. The firm has a market capitalization of $1.86 billion, a PE ratio of 50.83 and a beta of 0.48. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The stock’s fifty day moving average is $86.70 and its 200-day moving average is $81.48.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The business had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.ANI Pharmaceuticals’s revenue for the quarter was up 53.6% on a year-over-year basis. During the same quarter last year, the company posted $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. HC Wainwright upped their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Barclays started coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price for the company. JPMorgan Chase & Co. upped their price target on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Finally, Weiss Ratings downgraded ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $102.14.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ANIP. Arrowstreet Capital Limited Partnership acquired a new position in ANI Pharmaceuticals in the 3rd quarter worth about $32,992,000. Balyasny Asset Management L.P. grew its stake in shares of ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after buying an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $21,454,000. Rubric Capital Management LP increased its holdings in ANI Pharmaceuticals by 354.7% in the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after buying an additional 200,998 shares during the last quarter. Finally, UBS Group AG raised its position in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after acquiring an additional 185,172 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.